FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Kavthekar Atul 		2. Issuer Name and Ticker or Trading Symbol

Diplomat Pharmacy, Inc. [ DPLO ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
Chief Financial Officer
(Last)          (First)          (Middle)

4100 S. SAGINAW STREET 		3. Date of Earliest Transaction (MM/DD/YYYY)

3/18/2019
(Street)

FLINT, MI 48507
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   3/18/2019     A    15118   (1) A $0   28218   D    
Common Stock   3/19/2019     S    1265   (2) D $5.8436   (3) 26953   D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
(1)  On March 27, 2018, Mr. Kavthekar was granted restricted stock units that were subject to the issuer's satisfaction of certain financial performance criteria. On March 18, 2019 (the "determination date"), the performance criteria was met with respect to 15,118 restricted stock units. One-third of the restricted stock units vested upon the determination date, and the remaining two-thirds will vest in two equal installments on each anniversary of the determination date, subject to continued employment.
(2)  The sales reported in this Form 4 represent shares sold to cover the tax liability incurred incident to the delivery of shares of common stock from the previously awarded restricted stock units.
(3)  The price represents the weighted average price of the multiple transactions reported on this line. The shares were sold at prices ranging from $5.80 to $5.8525 per share. Upon request by the SEC staff, the issuer or any securityholder of the issuer, the reporting person will provide full information regarding the number of shares sold at each separate price.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Kavthekar Atul
4100 S. SAGINAW STREET
FLINT, MI 48507

Chief Financial Officer

Signatures
/s/ Christina Flint, by Power of Attorney 3/20/2019
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Diplomat Pharmacy (NYSE:DPLO)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Diplomat Pharmacy Charts.
Diplomat Pharmacy (NYSE:DPLO)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Diplomat Pharmacy Charts.